Rezum® is a new convection-based thermal treatment for lower urinary tract discomfort caused by benign prostatic hyperplasia (BPH) (LUTS). This study examines its safety, effectiveness, cost, and prospective involvement in the BPH/LUTS therapy paradigm. Rezum data is largely derived on a large randomised controlled study of 197 patients with a four-year follow-up period. Rezum Effectiveness ® ‘s and safety are further supported by four other trials, including one prospective pilot study, one crossover study, and two retrospective investigations. IPSS, QoL, Qmax, and PVR scores improved over time without compromising sexual function.
Rezum® is a cost-effective and safe treatment option for BPH/LUTS, and it should be evaluated as a possible first-line therapy for individuals with moderate to severe symptoms.
Reference: https://link.springer.com/article/10.1007/s11934-020-01018-6
